In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Protara Therapeutics, with a price target of $23.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the potential of Protara Therapeutics’ TARA-002 in the treatment of non-muscle invasive bladder cancer (NMIBC). The feedback from key opinion leaders (KOLs) suggests that TARA-002, a formulation of group A Streptococcus pyogenes, shows promising efficacy and safety profiles, making it a strong candidate in the BCG-naïve NMIBC space. The therapy’s ability to induce a higher cytotoxic response and a pronounced anti-tumor effect compared to BCG positions it as a viable alternative, especially given the current BCG shortages and the need for effective treatments for high-risk patients.
Moreover, the simplicity of TARA-002’s administration and its compatibility with existing medical practices further support its potential integration into treatment protocols. KOLs have indicated that if TARA-002 meets certain clinical benchmarks, it could be considered for a significant portion of BCG-naïve high-risk patients. This potential, combined with the ongoing challenges faced by competing therapies, reinforces the Buy rating and suggests that TARA-002 could play a meaningful role in the NMIBC treatment landscape.
In another report released on November 20, Oppenheimer also reiterated a Buy rating on the stock with a $25.00 price target.